Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 39

Sort by

Sort Order Select

Journal Articles

Chromatin Structure Dynamics Preserve Genome Stability in Multiple Myeloma

Antonis Kokkalis, PhD MSc, Praveen Anand, PhD, Monica S. Nair, Johannes M. Waldschmidt, MD, Julia Frede, PhD MPhil, Tushara Vijaykumar, Amy Guillaumet-Adkins, PhD, Valeriya Dimitrova, Birgit Knoechel, MD PhD, Jens G. Lohr, MD PhD

Blood (2019) 134 (Supplement_1): 1777.

https://doi.org/10.1182/blood-2019-127495

Published: 2019

Journal Articles

Compared the Effect of Mitroxantrone ( MA) with Idarubicine (IA) for Acute Myeloid Leukemia Induction Therapy

Peilong Lai, Mingyan Wu, Minming Li, Chengxin Deng, Zesheng Lu, Chenwei Luo, Xin Huang, Pengjun Liao, Lisi Huang, Ping Wu, Wang Yulian, Changchun Wan, Wei Ling, Liye Zhong, Suijing Wu, Xin Du, MD PhD, Jianyu Weng, MD

Blood (2018) 132 (Supplement 1): 5229.

https://doi.org/10.1182/blood-2018-99-116234

Published: 2018

Journal Articles

Early Detection and Molecular Characterization of Therapy-Related Leukemia in Children Reveals Patterns of Disease Transformation and Guides Future Surveillance Protocols

Barbara Spitzer, MD, Gunes Gundem, PhD, Noushin Farnoud, PhD, Nathan Millard, MD, Erin McGovern, BA, Minal Patel, BA, Max Levine, MS, Juan Medina, MS, Yangyu Zhou, BS, Juan E. Arango Ossa, BS, Michael Francis Walsh, MD, Ross L. Levine, MD, Irene Y. Cheung, ScD, Scott A. Armstrong, MD PhD, Nai-Kong V. Cheung, MD PhD, Elli Papaemmanuil, PhD

Blood (2018) 132 (Supplement 1): 291.

https://doi.org/10.1182/blood-2018-99-120005

Published: 2018

Journal Articles

Final Results of Phase 2, Open-Label Study of E7070, Idarubicin and Cytarabine in Patients (Pts) with Relapsed or Refractory (R/R) Acute Myeloid Leukemia (AML) and High-Risk Myelodysplastic Syndrome (MDS)

Rita Assi, MD, Hagop M. Kantarjian, MD, Jorge E. Cortes, MD, Tapan Kadia, MD, Naveen Pemmaraju, MD, Elias J. Jabbour, MD, Nitin Jain, MD, Naval Daver, MD, Taisuke Uehara, Takashi Owa, PhD, Gautam Borthakur, MD

Blood (2017) 130 (Supplement 1): 1380.

https://doi.org/10.1182/blood.V130.Suppl_1.1380.1380

Published: 2017

Journal Articles

Generation and Application of T-Cell Lymphoma Patient Derived Tumor Xenograft Models

Blood (2017) 130 (Supplement 1): 109.

https://doi.org/10.1182/blood.V130.Suppl_1.109.109

Published: 2017

Journal Articles

Phase 1/2 Study of Orociep All Oral Regimen with Idarubicin, Cyclophosphamide, Etoposide, Prednisolone in Combination to Intravenous Rituximab in Elderly Patients with Disseminated High Grade Non Hodgkin Lymphoma. Final Analysis

Stephanie Guidez, Laurence lacotte-Thierry, Cecile Tomowiak, MD, Antoine Machet, Carine Motard, Anthony Levy, Cécile Gruchet, Florence Sabirou, Arthur Bobin, Niels Moya, Thomas Systchenko, Jocelyn Barrier, MD, Carine le Du, Emmanuel Fleck, MD, Diane Chuillet-Moreau, Michele Chabin, Xavier Leleu, MD PhD, Joelle Guilhot, PhD, Vincent Delwail, MD

Blood (2017) 130 (Supplement 1): 5207.

https://doi.org/10.1182/blood.V130.Suppl_1.5207.5207

Published: 2017

Journal Articles

Clonal Selection in Therapy Related Myelodysplastic Syndromes Under Azacitidine Treatment

Anne Calleja, Chimene Moreilhon, PhD, Jean Michel Karsenti, MD, Lauris Gastaud, MD, Lionel Mannone, MD, Berengere Dadone, MD, Guillaume Robert, PhD, Patrick Auberger, PhD, Sophie Raynaud, MD PhD, Thomas Cluzeau, MDPhD

Blood (2017) 130 (Supplement 1): 5297.

https://doi.org/10.1182/blood.V130.Suppl_1.5297.5297

Published: 2017

Journal Articles

Targeting DNA Repair Mechanisms to Overcome Drug Resistance in Diffuse Large B Cell Lymphoma

Julie Devin, Yea-Lih Lin, PhD, Alboukadel Kassambara, PhD, Guillaume Cartron, Olivier Elemento, PhD, Angelos Constantinou, PhD, Philippe Pasero, PhD, Caroline Bret, PhD PharmD, Jerome Moreaux, PhD

Blood (2017) 130 (Supplement 1): 1479.

https://doi.org/10.1182/blood.V130.Suppl_1.1479.1479

Published: 2017

Journal Articles

A Precision Medicine Approach Incorporating Both Molecular and In Vitro Functional Data to Treat Patients with Relapsed/Refractory Acute Myeloid Leukemia

Blood (2016) 128 (22): 4043.

https://doi.org/10.1182/blood.V128.22.4043.4043

Published: 2016

Journal Articles

TOP2A a New Predictive Marker of Response to Carfilzomib in Multiple Myeloma

Antonia Reale, MD Oncologist in training, Tiffany Khong, BSc, PhD, Sridurga Mithraprabhu, PhD, John Reynolds, Malarmathy Ramachandran, Ioanna Savvidou, MD PhD, Krystal Bergin, Jay Hocking, MD PhDstudent, Andrew Spencer

Blood (2016) 128 (22): 4461.

https://doi.org/10.1182/blood.V128.22.4461.4461

Published: 2016

Journal Articles

A Series of 116 Therapy-Related Myeloid Neoplasms (t-MN) Patients from 2 French Comprehensive Cancer Centers

Hind Bennani, PharmD, Véronique Saada, PharmD, Christophe Willekens, MD, Jacques Vargaftig, MD

Blood (2015) 126 (23): 1322.

https://doi.org/10.1182/blood.V126.23.1322.1322

Published: 2015

Journal Articles

Identifying Targets for Therapy in High Risk t(4;14) Myeloma Using Multi-Level Molecular and Phenotypic Analysis of Isogenic MMSET and MMSET Knock out Cell Lines

Charlotte Pawlyn, MB BChir, Tim Chambers, Veronica Macleod, Daniel Sappington, Amy Buros, PhD, Caleb K. Stein, MS, Martin F Kaiser, MD, Rosemary Burke, Swen Hoelder, Gunnar Boysen, Ricky D Edmondson, PhD, Gareth J Morgan, MD PhD, Faith E Davies, MD

Blood (2015) 126 (23): 1792.

https://doi.org/10.1182/blood.V126.23.1792.1792

Published: 2015

Journal Articles

Eligibility Criteria Are Not Associated with Expected or Observed Adverse Events in Randomized Controlled Trials (RCTs) of Hematologic Malignancies

Abby Statler, MPH, MA, Tomas Radivoyevitch, PhD, Caitlin Siebenaller, PharmD, BCOP, Aaron T. Gerds, MD MS, Matt Kalaycio, MD, Eric Kodish, MD, Sudipto Mukherjee, MD PhD, Connie Cheng, PharmD, BCOP, Mikkael A. Sekeres, MD MS

Blood (2015) 126 (23): 635.

https://doi.org/10.1182/blood.V126.23.635.635

Published: 2015

Journal Articles

An Analysis of Prognostic Markers and the Performance of Scoring Systems in 1837 Patients with Therapy-Related Myelodysplastic Syndrome - a Study of the International Working Group (IWG-PM) for Myelodysplastic Syndromes (MDS)

Andrea Kuendgen, MD, Heinz Tuechler, Meritxell Nomdedeu, Guillermo Garcia-Manero, MD, Rami S. Komrokji, MD, Mikkael A. Sekeres, MD MS, Matteo Giovanni Della Porta, MD, Alan F List, MD, Mario Cazzola, Amy E. DeZern, MD MHS, Gail J. Roboz, MD, David P. Steensma, MD, Arjan A van de Loosdrecht, MD PhD, Arjan A van de Loosdrecht, MD PhD, Richard F. Schlenk, MD, Xavier Calvo, Sabine Blum, Arturo Pereira, Peter Valent, MD, Dolors Costa, Aristoteles Giagounidis, MD PhD, Luis Benlloch, Uwe Platzbecker, MD, Carmen Pedro, MD, Michael Lübbert, MD, Maria Teresa Cedena, Sigrid Machherndl-Spandl, MD, Maria Lopez-Pavia, MD, Detlef Haase, MD, Ana Africa Martin, Claudia D Baldus, MD, Montserrat Martínez de Sola, Reinhard Stauder, MD MSc, Brayan Merchan, MD, Claudia Mende, María Teresa Ardanaz, MD, Christina Ganster, Francesc Cobo, Thomas Schroeder, MD, Jordi Esteve, Rainer Haas, MD, Nomdedeu Benet, Peter L. Greenberg, MD, Ulrich Germing, MD, Guillermo Sanz, MD PhD

Blood (2015) 126 (23): 609.

https://doi.org/10.1182/blood.V126.23.609.609

Published: 2015

Journal Articles

Big Data Approach to Identify Molecular Basis for Drug Sensitivity Phenotypes in Acute Myeloid Leukemia

Su-In Lee, PhD, Benjamin Logsdon, PhD, Akanksha Saxena, BS, Vivian Oehler, MD, Chris P. Miller, PhD, C. Anthony Blau, MD, Pamela S. Becker, MD PhD

Blood (2014) 124 (21): 265.

https://doi.org/10.1182/blood.V124.21.265.265

Published: 2014

Journal Articles

Comparative Analysis of in Vitro Chemosensitivity to Four Proteasome Inhibitors in Human Myeloma Cell Lines

Amit Kumar Mitra, PhD, Taylor S Harding, B.A., Brian Van Ness, PhD

Blood (2014) 124 (21): 3436.

https://doi.org/10.1182/blood.V124.21.3436.3436

Published: 2014

Journal Articles

Maintenance of Respiration Capacity Is an Early Predictor of Drug Resistance in Cancer Cells

Cornelia A Brendel, MD, Katharina Henkenius, Melanie Maerken, Tom Kaiser, Larissa Greif, Stephan Metzelder, MD, Miriam Rehberger, Andreas Neubauer, MD

Blood (2014) 124 (21): 2157.

https://doi.org/10.1182/blood.V124.21.2157.2157

Published: 2014

Journal Articles

Inhibition Of Wee1 Enhances The Anti-Leukemic Effects Of Antimetabolites In Vitro and In Vivo

James B. Ford, DO, Susan Fosmire, Annemie van Linden, Ph.D., Dmitry Baturin, MD/PhD, Christopher C. Porter, MD

Blood (2013) 122 (21): 1281.

https://doi.org/10.1182/blood.V122.21.1281.1281

Published: 2013

Journal Articles

Strategies To Identify Effective Treatments For Proteasome Inhibitor Resistant Multiple Myeloma

Brian Van Ness, Ph.D, Holly A. F. Stessman, Ph.D., Linda B. Baughn, Ph.D., Aatif Mansoor, Amit Mitra, Nathan G. Dolloff, PhD, Chad L. Myers, PhD, Fenghuang Zhan, MD&PhD, Taylor Harding, B.S.

Blood (2013) 122 (21): 278.

https://doi.org/10.1182/blood.V122.21.278.278

Published: 2013

Journal Articles

Drug-Induced Cytokine Release Sensitizes Protective Tumor Microenvironments to Antibody- Mediated Therapy

Christian P. Pallasch, MD, Leskov Ilya, MD, PhD, Yadira M Soto, Christian J. Braun, MD, Nadine Kutsch, MD, Adam Drake, PhD, Lukas P. Frenzel, MD, Bettina Iliopoulou, PhD, Nico van Rooijen, PhD, Clemens Wendtner, MD, Michael Hallek, MD, Jianzhu Chen, PhD, Michael T Hemann, PhD

Blood (2012) 120 (21): 1335.

https://doi.org/10.1182/blood.V120.21.1335.1335

Published: 2012

NARROW

Chromatin Structure Dynamics Preserve Genome Stability in Multiple Myeloma

Compared the Effect of Mitroxantrone ( MA) with Idarubicine (IA) for Acute Myeloid Leukemia Induction Therapy

Early Detection and Molecular Characterization of Therapy-Related Leukemia in Children Reveals Patterns of Disease Transformation and Guides Future Surveillance Protocols

Final Results of Phase 2, Open-Label Study of E7070, Idarubicin and Cytarabine in Patients (Pts) with Relapsed or Refractory (R/R) Acute Myeloid Leukemia (AML) and High-Risk Myelodysplastic Syndrome (MDS)

Generation and Application of T-Cell Lymphoma Patient Derived Tumor Xenograft Models

Phase 1/2 Study of Orociep All Oral Regimen with Idarubicin, Cyclophosphamide, Etoposide, Prednisolone in Combination to Intravenous Rituximab in Elderly Patients with Disseminated High Grade Non Hodgkin Lymphoma. Final Analysis

Clonal Selection in Therapy Related Myelodysplastic Syndromes Under Azacitidine Treatment

Targeting DNA Repair Mechanisms to Overcome Drug Resistance in Diffuse Large B Cell Lymphoma

A Precision Medicine Approach Incorporating Both Molecular and In Vitro Functional Data to Treat Patients with Relapsed/Refractory Acute Myeloid Leukemia

TOP2A a New Predictive Marker of Response to Carfilzomib in Multiple Myeloma

A Series of 116 Therapy-Related Myeloid Neoplasms (t-MN) Patients from 2 French Comprehensive Cancer Centers

Identifying Targets for Therapy in High Risk t(4;14) Myeloma Using Multi-Level Molecular and Phenotypic Analysis of Isogenic MMSET and MMSET Knock out Cell Lines

Eligibility Criteria Are Not Associated with Expected or Observed Adverse Events in Randomized Controlled Trials (RCTs) of Hematologic Malignancies

An Analysis of Prognostic Markers and the Performance of Scoring Systems in 1837 Patients with Therapy-Related Myelodysplastic Syndrome - a Study of the International Working Group (IWG-PM) for Myelodysplastic Syndromes (MDS)

Big Data Approach to Identify Molecular Basis for Drug Sensitivity Phenotypes in Acute Myeloid Leukemia

Comparative Analysis of in Vitro Chemosensitivity to Four Proteasome Inhibitors in Human Myeloma Cell Lines

Maintenance of Respiration Capacity Is an Early Predictor of Drug Resistance in Cancer Cells

Inhibition Of Wee1 Enhances The Anti-Leukemic Effects Of Antimetabolites In Vitro and In Vivo

Strategies To Identify Effective Treatments For Proteasome Inhibitor Resistant Multiple Myeloma

Drug-Induced Cytokine Release Sensitizes Protective Tumor Microenvironments to Antibody- Mediated Therapy

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only